Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00643929

LENS - Long-term Eltrombopag Observational Study — LENS  

Purpura, Thrombocytopaenic, Idiopathic Clinical Trial

Official title:
LENS - Long-term Eltrombopag Observational Study - A Long Term Observational Ocular Safety Follow-up Study in Adults Who Have Received Study Medication (SB-497115-GR / Eltrombopag Olamine or Placebo) in a Phase II or III Clinical Study Evaluating Eltrombopag

Clinical Trial Summary

A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00643929
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date February 2007
Completion date March 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT00908037 - Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT00442871 - Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment Phase 1
Completed NCT01098487 - A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Phase 4
Withdrawn NCT01440361 - A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. Phase 2
Completed NCT01064336 - Promacta Pregnancy Registry N/A
Completed NCT00424177 - Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Phase 2
Completed NCT00351468 - EXTEND (Eltrombopag Extended Dosing Study) Phase 3
Completed NCT00688272 - Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag Phase 1
Completed NCT01072162 - Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect Phase 1
Completed NCT00102739 - SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT01416311 - Drug Use Investigation for REVOLADE (ITP)
Completed NCT00359463 - Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment Phase 1